News Rutgers Health Leading Program to Support MS Children Rutgers Health Leading Program to Support MS Children by Joana Carvalho, PhD | August 1, 2019 Share this article: Share article via email Copy article link Rutgers Health is leading the Pediatric Multiple Sclerosis and Demyelinating Diseases Program, the only program in the state of New Jersey designed specifically to support children with multiple sclerosis (MS). The support program seeks to promote children’s access to cutting-edge therapies and clinical trials, and to educate them and their family members about the disorder. Children participating in the program will have access to a personalized care plan that has been designed to help them face daily life challenges posed by MS. Statistics indicate that approximately 8,000 children in the U.S. alone are living with MS. The first signs of the disorder usually include changes in vision, difficulties in balance, weakness or loss of sensation in the arms and legs, bladder incontinence or urgency, and spinal cord inflammation. As with any disease an earlyĀ diagnosisĀ and prompt treatment can make the difference, and offer children the chance to lead a better life. Unlike adults, children tend to experience MS relapses more often because the disorder tends to be more inflammatory. For that reason, in order to prevent disease relapses and guarantee that children have the best quality of life possible, a combined approach of disease-modifying medications and complementary therapies (e.g., physical therapy) are warranted. “Every day that a patient lives with MS, the disease is working against them. The challenge is not knowing if what we do now will be effective in the future,”Ā Vikram Bhise, MD, said in a press release. Bhise is anĀ associate professor of pediatrics and chief of the division of child neurology and neurodevelopmental disabilities at Rutgers Robert Wood Johnson Medical School. Alexander Wallerson, one of Bhise’s patients, was diagnosed with relapsing-remitting MS (RRMS) when he was just 12 years old, after he started having trouble walking. “I walked like I was drunk,” said Wallerson, who now is 26 years old and lives in New Brunswick, New Jersey. “I was limping but not in pain.” While he was attending high school, Wallerson continued to experience on-off attacks of MS, in which he would have episodes of double-vision, numbness, or weakness in one side of his body. After discussing his symptoms with Bhise, he was prescribedĀ Rebif (interferon beta-1a), an immunomodulator medication that has been approved in the U.S. and the European Union for the treatment of RRMS, to control his symptoms. After starting his treatment regimen with Rebif injections every other day, his symptoms improved and Wallerson carried on with his life. He continued to practice sports, graduated near the top of his class, and received several scholarships for college. Although MS prevented him from becoming a neurosurgeon, Wallerson enrolled atĀ Rutgers University to study information technology, and is now a 3-D modeler working for a solar energy company. Print This Page About the Author Joana Carvalho, PhD Joana holds a bachelorās in biology, a Master of Science in evolutionary and developmental biology, and a PhD in biomedical sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells ā those that make up the lining of blood vessels ā found in the umbilical cord of newborns. In addition to several research fellowships, she was awarded two Erasmus scholarships to conduct part of her studies in France. Tags children, pediatric MS, relapse
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year
April 22, 2024 News by Margarida Maia, PhD Viatris launches low-dose Copaxone generic formulation in Canada
April 22, 2024 News by Marisa Wexler, MS AAN 2024: Briumvi found to ease disability in certain MS patients